Table 2.

Responsiveness to treatment with dopamine agonists in patients with prolactinomas in the context of a multiple endocrine neoplasia type 1

Author, year (reference)PatientsProlactinomas (%)MicroMacroDopamine agonist responders (%)
Burgess, 1996 (24)16518a757 (58.3)b
Verges, 2002 (25)32484 (26)137135 (42)
de Laat, 2015 (26)32350 (15.5)302031 (59.6)
Goroshi, 2016 (27)188 (44.4)358 (100)
Vannucci, 2017 (28)227 (31.8)525 (71.4)
Total852167 (19.6)58 (34.7)103 (61.7)86 (51.5)
Author, year (reference)PatientsProlactinomas (%)MicroMacroDopamine agonist responders (%)
Burgess, 1996 (24)16518a757 (58.3)b
Verges, 2002 (25)32484 (26)137135 (42)
de Laat, 2015 (26)32350 (15.5)302031 (59.6)
Goroshi, 2016 (27)188 (44.4)358 (100)
Vannucci, 2017 (28)227 (31.8)525 (71.4)
Total852167 (19.6)58 (34.7)103 (61.7)86 (51.5)

Six patients with normal pituitary scan.

Calculated on 12 patients with tumor evidence at pituitary scan.

Table 2.

Responsiveness to treatment with dopamine agonists in patients with prolactinomas in the context of a multiple endocrine neoplasia type 1

Author, year (reference)PatientsProlactinomas (%)MicroMacroDopamine agonist responders (%)
Burgess, 1996 (24)16518a757 (58.3)b
Verges, 2002 (25)32484 (26)137135 (42)
de Laat, 2015 (26)32350 (15.5)302031 (59.6)
Goroshi, 2016 (27)188 (44.4)358 (100)
Vannucci, 2017 (28)227 (31.8)525 (71.4)
Total852167 (19.6)58 (34.7)103 (61.7)86 (51.5)
Author, year (reference)PatientsProlactinomas (%)MicroMacroDopamine agonist responders (%)
Burgess, 1996 (24)16518a757 (58.3)b
Verges, 2002 (25)32484 (26)137135 (42)
de Laat, 2015 (26)32350 (15.5)302031 (59.6)
Goroshi, 2016 (27)188 (44.4)358 (100)
Vannucci, 2017 (28)227 (31.8)525 (71.4)
Total852167 (19.6)58 (34.7)103 (61.7)86 (51.5)

Six patients with normal pituitary scan.

Calculated on 12 patients with tumor evidence at pituitary scan.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close